These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10988097)

  • 1. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.
    Kirk O; Gatell JM; Mocroft A; Pedersen C; Proenca R; Brettle RP; Barton SE; Sudre P; Phillips AN
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):865-72. PubMed ID: 10988097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.
    Karakousis PC; Moore RD; Chaisson RE
    Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of tuberculosis or Mycobacterium avium-intracellulare complex infection in HIV-infected patients].
    Shirasaka T
    Kekkaku; 2007 Nov; 82(11):845-8. PubMed ID: 18078110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment].
    Schneider MM; Reiss P; Borleffs JC; Rozenberg-Arska M; Hoepelman IM
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):80-3. PubMed ID: 9036351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].
    Mary-Krause M; Rabaud C; Jouan M; Obadia M; de la Blanchardière A; Raffi F; May T
    Pathol Biol (Paris); 2000 Jun; 48(5):495-504. PubMed ID: 10949848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
    Brooks JT; Song R; Hanson DL; Wolfe M; Swerdlow DL;
    Clin Infect Dis; 2005 Aug; 41(4):549-53. PubMed ID: 16028167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.
    Furrer H; Telenti A; Rossi M; Ledergerber B
    AIDS; 2000 Jul; 14(10):1409-12. PubMed ID: 10930156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy.
    Rossi M; Flepp M; Telenti A; Schiffer V; Egloff N; Bucher H; Vernazza P; Bernasconi E; Weber R; Rickenbach M; Furrer H;
    Swiss Med Wkly; 2001 Aug; 131(31-32):471-7. PubMed ID: 11641970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
    Aberg JA; Williams PL; Liu T; Lederman HM; Hafner R; Torriani FJ; Lennox JL; Dube MP; MacGregor RR; Currier JS;
    J Infect Dis; 2003 Apr; 187(7):1046-52. PubMed ID: 12660918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
    Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterial diseases and HIV.
    Pozniak A
    J HIV Ther; 2002 Feb; 7(1):13-6. PubMed ID: 11956499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy.
    Gill J; Moyle G; Nelson M
    AIDS; 1998 Apr; 12(6):680. PubMed ID: 9583614
    [No Abstract]   [Full Text] [Related]  

  • 19. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
    Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
    Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.